Amgen AMGN announced that the European Commission (“EC”) has approved Imdylltra (tarlatamab) to treat adults with ...

Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, ...

With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, ...

Amgen's fair value estimate has been nudged from US$349.66 to US$352.23 per share, a small move that still matters if you are ...

Jefferies Global Healthcare Conference 2026 June 4, 2026 9:55 AM EDTCompany ParticipantsPeter Griffith - Executive VP & ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), albeit ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

The U.S. Food and Drug Administration's Center ​for Drug Evaluation ‌and Research on Monday proposed withdrawing approval of Amgen's ​drug for a ​group of rare autoimmune ⁠diseases, citing a lack ​of ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.